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1
I. BACKGROUND

I spent the summers of 2009 and 2010 working at the Mayo Clinic in Rochester, Minnesota,
as part of their Graduate School’s Summer Undergraduate Research Fellowship (SURF)
program. The SURF program provides the opportunity for undergraduate students from
universities across the country to work in one of the many labs on the Mayo Clinic campus.
In addition to working on a research project, SURF students present their results to their
department at the end of the summer in the form of an oral presentation and a poster session,
and are able to attend seminars almost daily during their time at Mayo. I spent both summers
working in a laboratory in the Molecular Neuroscience Department under the direction of
Joseph Poduslo, Ph.D. The work was directed towards understanding the mechanism of
Alzheimer’s Disease (AD) and developing an immunotherapeutic treatment. This report
summarizes the work I completed towards these objectives.
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II. INTRODUCTION

Alzheimer’s Disease (AD) is a progressive and fatal neurodegenerative condition. AD is the
most common form of senile dementia, accounting for roughly 60% of all dementia cases,
and is the fourth leading cause of death in developed nations. Today, over 5 million
Americans are living with AD and there are at least 26.6 million people afflicted worldwide.
Common symptoms of Alzheimer’s Disease are memory loss, a decline in physical
coordination, and personality changes.

AD is characterized pathologically by the presence of extracellular amyloid plaques,
neurofibrillary tangles, cerebrovascular amyloid deposits, and intraneuronal accumulation of
amyloid-beta peptides. These amyloid-beta peptides (Aβ) are produced by the cleavage of
amyloid precursor protein, an integral membrane protein. When amyloid precursor protein
(APP) is cleaved by both beta- and gamma-secretases, the neurotoxic peptide fragments
amyloid-beta 40 (Aβ40) and amyloid-beta 42 (Aβ42) are formed, as in Figure 1 (page 3).
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Figure 1. Processing of amyloid precursor protein (APP).

These peptides constitute extraneuronal plaques and deposits, and it is believed that the
increased production and intraneuronal accumulation of these peptides leads to
neurodegeneration and AD. Additionally, it has been suggested that soluble oligomers of Aβ,
rather than amyloid fibrils or monomers, initiate the cognitive dysfunction observed in AD.
My studies were performed using Aβ40, though the striking similarity between the two
peptides (Aβ42 has two additional amino acids) suggests that the two behave similarly in
vivo.

Previous research performed in the lab suggested that three amino acids present within both
Aβ40 and Aβ42 are integral to the neuronal binding and internalization of these peptides.
These amino acids are the histidine residues at positions 13 and 14, as well as the glycine
residue at position 33. For the complete amino acid sequence of Aβ40, see Figure 2 (page 4).
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Figure 2. Amino acid sequence of Aβ40, with residues of interest in red.

The goal of my project was to block the neuronal binding and internalization of Aβ40. I
attempted to do this using a human monoclonal antibody that binds to positions 2011 on Aβ
(IgG-4.1). We hypothesized that IgG-4.1 would function as a blocking antibody to Aβ40 by
sterically hindering the histidine residues at positions 13 and 14. This steric hindrance of key
amino acids should interfere with the neuronal interaction of Aβ40, thereby prevents its
binding and internalization.

My research also examined the roles that histidine-13, histidine-14, and glycine-33 play in
the neuronal binding and internalization of Aβ40. I did this by studying not only native
Aβ40, but also substituted derivatives of the peptide. I examined Aβ40 with the histidine
residues at positions 13 and 14 substituted to glycine (Aβ40 H13,14G), and Aβ40 with an
additional substitution of the glycine residue at position 33 to alanine (Aβ40 H13,14G;
G33A. My hypothesis was that Aβ40 H13,14G and Aβ40 H13,14G; G33A would both have
lowered levels of binding and internalization as compared to Aβ40.
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III. EXPERIMENTAL METHODS

A cell line derived from the pheochromocytoma of the rat adrenal medulla called “PC-12”
was used as a model cell system for human neurons. These cells stop proliferating and
differentiate when treated with a protein known as nerve growth factor (NGF). When fully
differentiated (after six days of treatment with NGF), PC-12 cells have grown dendrite-like
extensions and wholly resemble neurons in both function and appearance.

PC-12 cells were maintained in a Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% horse serum, 10% newborn calf serum, and 1%
penicillin/streptomycin. PC-12 cells were plated on six-well plates that had been treated with
poly-L-Lysine. This poly-L-Lysine was applied to wells at a concentration of 0.1 mg/mL and
was allowed to incubate in the wells overnight at 37°C. After the overnight incubation, the
poly-L-Lysine was removed from the wells. The plates were rinsed twice with Dulbecco’s
Phosphate Buffered Saline without calcium and magnesium and allowed to dry for a
minimum of two hours. The PC-12 cells were then plated at a cell density of 25,000 cells per
well in supplemented DMEM containing 100 ng/mL Nerve Growth Factor (NGF). The PC12 cells were then allowed to differentiate for six days. The supplemented DMEM media
containing NGF was changed on the cells every two days during differentiation.

In order to allow for determination of the amount of peptide associated with the cell samples
at the end of an experiment, peptides were synthesized with the fluorochrome fluorescein
isothiocyanate (FITC). This fluorescent dye allowed for the determination of the geometric
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mean fluorescence of the cells via flow cytometry, since flow cytometry allows for
measurement of the fluorescence emission of cells. In a flow cytometer, the cell suspension is
first focused into a single cell wide laminar flow column. This fluid column is then passed
through a laser beam, which hits the cells one at a time as the column passes through the
beam. When cells that had taken up FITC-labeled peptide pass through the laser beam, they
emitted fluorescence that was detected and recorded by the flow cytometer. The geometric
mean fluorescence of the cell samples was determined by the flow cytometer in this way, and
was directly proportional to the amount of fluorescent-labeled peptide (F-Aβ40, F-Aβ40
H13,14G, or F-Aβ40 H13,14G; G33A) associated with the cells.

Differentiated PC-12 cells were treated with various experimental “plating mixes” and
allowed to incubate at 37°C for one hour. These plating mixes contained one of the four
different fluorescent-labeled peptides (5 µM peptide), or one of the fluorescent-labeled
peptides (2.5 µM peptide) that had been pre-incubated with IgG-4.1 at a 1:1 ratio. A control
plating mix containing only Hank’s Balanced Salt Solution (with calcium and magnesium +
10 mM HEPES, pH 7.4) was used to measure the amount of background fluorescence, and a
plating mix containing human transferrin conjugated to AlexaFluor633 (20 mM transferrin),
a marker for endocytosis, was used to ensure healthy, viable cells.

After the one hour incubation time, the plating mixes were pulled off and the cells were
removed from the wells using either a non-enzymatic Cell Dissociation Buffer (1X) or
trypsin (0.0125%). The non-enzymatic treatment allowed for removal of the cells from the
wells without cleaving off any peptide bound to the exterior of the cells, whereas trypsin
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cleaved any peptide that was associated with the exterior of the cell, thereby leaving the cells
with just the internalized peptide. The use of these two different treatments allowed for the
differentiation between the total amount of peptide associated with the cells (as displayed by
the geometric mean fluorescence of Cell Dissociation Buffer-treated cells) and the amount of
peptide that had been internalized by the cells (as shown by the geometric mean fluorescence
of trypsin-treated cells). After the cells were removed from the wells, they were fixed in 1%
paraformaldehyde and analyzed on a FACSCalibur flow cytometer. This experimental set-up
is summarized in Figure 3.

Pre-incubated
Treatments
at 4°C for 1h

HBSS
Only

Transferrin
Only

Peptide
Only

Peptide
and IgG-4.1

Added to
Differentiated
PC12 Cells

Incubated
for 1h at 37°C

Detached with
Trypsin

Detached with Cell
Dissociation Buffer

Examined Binding
and Internalization
using Flow
Cytometry

Figure 3. Flowchart providing a summary of the experimental procedure.
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IV. RESULTS

The geometric mean fluorescence (GMF) values obtained from flow cytometry analysis of
each sample were directly proportional to the amount of associated peptide, which allowed
for GMF values to be used to quantify peptide binding and internalization. The obtained
GMF values for three trials of the experiment are presented in Appendix A (page 13). The
results of the experiments analyzing the effects of the various amino acid substitutions as
well as the presence of antibody are summarized in the form of charts describing GMF for
each experimental treatment in the following Figure 4 and Figure 5 (page 9). Figure 4
illustrates the GMF values for cells treated with cell dissociation buffer, representing the
amount of total associated protein, while Figure 5 gives the GMF values for cells treated with
trypsin, which represents the amount of internalized peptide. The cells treated with media
only (“Cells Only”) and with Transferrin were controls.
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Figure 4. Geometric mean fluorescence of cells treated with cell dissociation buffer.
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Figure 5. Geometric mean fluorescence of cells treated with trypsin.

The low GMF values for cells treated only with media suggest that the media used in the
experiments did not interfere with the flow cytometry analysis. The high GMF values for
cells treated with Transferrin reveals that the cells were healthy and were actively performing
endocytosis. The Transferrin levels were similar between cells treated with trypsin and with
cell dissociation buffer, which is as expected since Transferrin should be internalized via
endocytosis and not remain bound to the membrane. By comparing Figure 4 and Figure 5, it
can be observed that all GMF values of cells treated with trypsin are only slightly lower than
those treated with cell dissociation buffer.

The GMF values for cells treated with substituted F-Aβ40 were lower than those for cells
treated with wild type F-Aβ40. Each additional substitution further reduced the GMF value.
Additionally, cells that were incubated with plating mixes containing a peptide that had been

10
pre-incubated with IgG-4.1 exhibited a significant decrease in GMF as compared to cells
treated with peptide alone.
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V. DISCUSSION and CONCLUSION

Several important conclusions can be drawn from the results presented in Figures 4 and 5.
First, since the GMF values were very similar between cells treated with trypsin and cells
treated with cell dissociation buffer, it is clear that the majority of F-Aβ40 associated with
the cells was internalized by them, instead of remaining bound to the membrane. Secondly,
the GMF values decreased with each additional amino acid substitution, confirming previous
work that the histidine residues at 13 and 14 and the glycine residue at 33 are indeed
important in Aβ40 being internalized and accumulated. Finally, and most significantly, cells
that were incubated with plating mixes containing a peptide that had been pre-treated with
IgG-4.1 exhibited a significant decrease in GMF as compared to cells treated with just the
peptide. Clearly, the presence of IgG-4.1 blocked the internalization of F-Aβ40 as well as its
substituted derivatives.

These results obtained from PC12 cells can be extended to the neuronal binding and
internalization of F-Aβ40. Internalized peptide was found to be responsible for a large
proportion of the total amount of peptide associated with the neurons, and very little of it
remains bound to the membrane. Amino acid substitutions of F-Aβ40 decreased the levels of
binding and internalization of F-Aβ40, confirming the importance of the histidine residues at
positions 13 and 14 and the glycine residue at 33 in neuronal binding and internalization.
Most importantly, pre-treating F-Aβ40 and its derivatives with IgG4.1 decreased their
neuronal binding and internalization. This finding suggests that immunotherapy may play a
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role in reducing the intraneuronal accumulation of Aβ40, thus preventing the initiation of the
neurodegeneration associated with Alzheimer’s Disease.
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VI. APPENDIX A

Table 1: Geometric Mean Fluorescence Values for Three Experiment Trials
Trypsin

22-Jul-07

27-Jul-07

28-Jul-07

Average

Standard Deviation

Standard Error

2.2

3.1

3.5

3.0

0.7

0.39

Transferrin Only

151.1

139.6

165.8

152.2

13.1

7.57

F-AB40 Only

78.9

100.6

140.8

106.7

31.4

18.15

F-AB40/IgG-4.1

4.7

13.4

8.1

8.8

4.4

2.54

F-AB40 H13,14G Only

56.7

84.2

115.8

85.6

29.6

17.09

F-AB40 H13,14G/IgG-4.1

6.7

10.6

11.7

9.7

2.6

1.51

F-AB40 H13,14G; G33A Only

31.9

32.5

70.5

45.0

22.1

12.76

F-AB40 H13,14G; G33A/IgG-4.1

8.0

10.1

15.9

11.4

4.1

2.37

2.6

2.7

3.6

3.0

0.6

0.32

Transferrin Only

121.9

80.7

232.4

145.0

78.4

45.33

F-AB40 Only

135.5

96.9

212.3

148.2

58.8

33.96

9.5

11.9

18.3

13.2

4.5

2.63

F-AB40 H13,14G Only

104.2

77.6

147.1

109.6

35.1

20.28

F-AB40 H13,14G/IgG-4.1

15.7

20.8

27.9

21.4

6.1

3.55

F-AB40 H13,14G; G33A Only

54.5

43.6

94.4

64.2

26.7

15.45

F-AB40 H13,14G; G33A/IgG-4.1

10.0

22.8

19.2

17.3

6.6

3.80

Cells Only

Cell Dissociation Buffer
Cells Only

F-AB40/IgG-4.1

14
VII. REFERENCES
1. Harmeier A, et al. “Role of Amyloid-β Glycine 33 in Oligomerization, Toxicity, and
Neuronal Plasticity.” The Journal of Neuroscience, 2009; 29(23): 7582-7590.

2. Kandimalla KK, et al. “Mechanism of Neuronal versus Endothelial Cell Uptake of
Alzheimer’s Disease Amyloid β Protein.” PLoS One, 2009; 4(2): 1-20.

3. Poduslo JF, et al. “In vivo Targeting of Antibody Fragments to the Nervous System for
Alzheimer's Disease Immunotherapy and Molecular Imaging of Amyloid Plaques.”
Journal of Neurochemistry, 2007; 102(2): 420-433.

4. Poduslo JF, et al. “HH Domain of Alzheimer’s Disease Aβ Provides Structural Basis for
Neuronal Binding in PC12 and Mouse Cortical/Hippocampal Neurons.” PLoS One, 2010;
5(1): e8813.

